Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462837 · ClinicalTrials.gov registry record · Phase 2
Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement
A Phase 2 study, sponsored by Southern Illinois University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02462837 is a Phase 2 study that was terminated before completion, run by Southern Illinois University. The registered enrollment target is 11 participants.
The verdict
NCT02462837, a Phase 2 study, was terminated before completion, sponsored by Southern Illinois University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The objective of this pilot study is to assess whether Myrbetriq™ will improve post-operative ureteral pain and discomfort, reduce bladder storage symptoms and increase quality of life following ureteral stenting.
Interventions
- DRUG Placebo
- DRUG Mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02462837
The ClinicalTrials.gov registry entry for NCT02462837 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern Illinois University, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02462837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02462837 about?
NCT02462837 is a clinical study titled "Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement". The objective of this pilot study is to assess whether Myrbetriq™ will improve post-operative ureteral pain and discomfort, reduce bladder storage symptoms and increase quality of life following ureteral stenting.
What is the current status of trial NCT02462837?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2015-05. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT02462837?
The interventions under investigation include: Placebo (DRUG), Mirabegron (DRUG).
Who is sponsoring clinical trial NCT02462837?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.